Abstract: Objective To investigate the correlation of ERCCl, BRCAl proteins expression and clinicopathological features, chemotherapeutic effect and prognosis of Oxaliplatin regimens in advanced colon cancer tissues. Methods Immunohistochemistry was used to measure ERCCl and BRCAl proteins expression in advanced colon cancer tissues. Results The positive rate of ERCCl and BRCAl proteins expression were 41.2% and 47.4% respectively. ERCCl and BRCAl proteins expression were not associated with gender, age, differentiation degree or the position of tumor(P＞0.05). The positive expression of ERCCl protein had a significantly positive correlation with that of BRCA1 protein in advanced colon cancer(r=0.211, P=0.038). The response rate of chemotherapy in patients with ERCCl and BRCAl negative expression was significantly higher than that with positive expression(P＜0.05). Compared with ERCCl positive patients, ERCCl negative patients had longer median survival time(MST) with statistical difference(P=0.014). Compared with BRCAl positive patients, BRCAl negative patients had longer MST without statistical difference(P=0.201). COX multivariate analysis showed that ERCC1 protein expression and differentiation degree were independently factors correlated with the prognosis of advanced colon cancer patients. Conclusion The expression of ERCCl and BRCA1 had a significant correlation. ERCC1 is a predictive marker for chemotherapeutic effect and prognosis of platinum-based regiment, however, BRCA1 is only a predictive factor for chemotherapeutic effect on advanced colon cancer patients and its value in the prognosis still needs more investigation.